, Volume 34, Supplement 1, pp 134–138 | Cite as

The Possible Role of Quinolones in Yersiniosis

  • J. A. A. Hoogkamp-Korstanje
Section 5: Ofloxacin in Other Infections


The in vitro susceptibility of 135 strains of Yersinia enterocolitica was tested by agar dilution. About 85% of the strains were susceptible to trimethoprim (1 mg/L), tetracycline (4 mg/L), chloramphenicol (4 mg/L) and cefuroxime (8 mg/L); 90 to 100% to piperacillin (16 mg/L), cefotaxime (8 mg/L) and gentamicin (1 mg/L); 100% to ciprofloxacin (≤ 0.016 mg/L), ofloxacin (0.06 mg/L) and pefloxacin (0.12 mg/L).

The outcome of 88 patients, treated for various forms of yersiniosis, showed 15% failure for trimethoprim or co-trimoxazole and tetracycline and 70% failure for cephalosporins and aminoglycoside-β-lactam combinations.

Four patients were successfully treated with ciprofloxacin 500mg orally or 300mg intravenously administered twice daily for up to 6 weeks.


Ofloxacin Quinolones Trimethoprim Cefuroxime Piperacillin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Auckenthaler R, Michea-Hamzehpour M, Pechere JC. In vitro activity of newer quinolones against aerobic bacteria. Journal of Antimicrobial Chemotherapy 17 (Suppl. B): 29–39, 1986PubMedCrossRefGoogle Scholar
  2. Bergogne-Berezin E. Penetration of ciprofloxacin into tissue: a review. In Neu & Weuta (Eds) Proceedings First International Ciprofloxacin Workshop, pp. 183–188, Excerpta Medica, Amsterdam, 1986Google Scholar
  3. Bottone EJ. Atypical Yersinia enterocolitica.clinical and epidemiological parameters. Journal of Clinical Microbiology 7: 562–567, 1978PubMedGoogle Scholar
  4. Bottone EJ, Sheehan DJ. Yersinia enterocolitica: guidelines for serologic diagnosis of human infections. Review of Infectious Diseases 5: 898–906, 1983CrossRefGoogle Scholar
  5. Deleers L, Roekaerts F. Effectiveness of ofloxacin in the treatment of wound infections. Fourteenth International Congress of Chemotherapy, Kyoto, June 23–28. Abstract no. S-31-12, 1985Google Scholar
  6. Dutch Group Standardisation Susceptibility Testing. In Mouton, Van Klingeren (Eds) Standaardisatie van Gevoeligheidsbepalingen. RIVM, Bilthoven, The Netherlands, 1981Google Scholar
  7. Heesemann J, Eggers Ch, Schröder J, Laufs R. Serological diagnosis of yersiniosis by the immunoblottechnique using plasmid-encoded antigens of Yersinia enterocolitica. In Simon & Wilkinson (Eds) Diagnosis of infectious diseases — new aspects, pp. 79–88, Schattauer, Stuttgart-New York, 1986Google Scholar
  8. Hoogkamp-Korstanje JAA. Yersiniosis in childhood: incidence and diagnosis. In Simon & Wilkinson (Eds) Diagnosis of infectious diseases — New aspects, pp. 69–77, Schattauer, Stuttgart-New York, in press Hoogkamp-Korstanje JAA, Klein S. Ciprofloxacin in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 18: 407–413, 1986PubMedCrossRefGoogle Scholar
  9. Hoogkamp-Korstanje JAA, Meijer CA. In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gramnegative bacteria tested with a modified agar dilution method. European Journal of Clinical Microbiology 1: 166–170, 1982PubMedCrossRefGoogle Scholar
  10. Hoogkamp-Korstanje JAA, Van Oort HJ, Schipper JJ, Van der Wal T. Interprostatic concentration of ciprofloxacin and its activity against urinary pathogens. Journal of Antimicrobial Chemotherapy 14: 641–645, 1984PubMedCrossRefGoogle Scholar
  11. Hoogkamp-Korstanje JAA, De Koning J, Samson JP. Incidence of human infection with Yersinia enterocoliticaserotypes 03, 08 and 09 and the use of indirect immunofluorescence in diagnosis. Journal of Infectious Diseases 153: 138–141, 1986PubMedCrossRefGoogle Scholar
  12. Schönwald S, Breitenfeld V, Car V, Gmajnicki B. Treatment of acute diarrhoeal syndrome with ciprofloxacin. In Neu & Weuta (Eds) First International Ciprofloxacin Workshop, pp. 353–356, Excerpta Medica, Amsterdam, 1986Google Scholar
  13. Soriano F, Vega J. The susceptibility of Yersinia to eleven antimicrobials. Journal of Antimicrobial Chemotherapy 10: 543–547, 1982PubMedCrossRefGoogle Scholar
  14. Tacket CO, Davis BR, Carter GJPJ, Randolph JF, Cohen ML. Yersinia enterocolitica pharyngitis. Annals of Internal Medicine 99: 40–42, 1983PubMedGoogle Scholar
  15. WHO Report. Yersiniosis. Euroreports and studies 60. Copenhagen, 1983Google Scholar

Copyright information

© ADIS Press Limited 1987

Authors and Affiliations

  • J. A. A. Hoogkamp-Korstanje
    • 1
  1. 1.Laboratory for Public HealthLeeuwardenThe Netherlands

Personalised recommendations